Skip to content

US · TEM · MEDICAL - HEALTHCARE INFORMATION SERVICES

Tempus AI, Inc. (TEM) intrinsic value and stock valuation

$54.04as of 2026-11-21 · Mkt cap 8.18B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tempus AI, Inc. DCF and intrinsic value

InvestorsCraft values TEM with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from TEM’s statements →

Tempus AI, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Chicago, IL 60654 tempus.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$1.27B+46.6% 5y CAGRd
20192025
Net income
-$-245.03M
20192025
Free cash flow
-$-245.35M
20192025
Total equity
$491.3M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$1.27B$693.4M$531.8M$320.7M$257.9M
Operating income-$-252.87M-$-691.08M-$-196.08M-$-265.44M-$-243.71M
Net income-$-245.03M-$-705.81M-$-214.12M-$-289.81M-$-259.19M
EPSd-$-1.41M-$-4.35M-$-1.39M-$-1.71M-$-1.53M
Operating cash flow-$-218.09M-$-189.04M-$-214.34M-$-168.2M-$-211.98M
Capital expenditure-$-27.27M-$-22.12M-$-34.61M-$-18.38M-$-11.77M
Free cash flow-$-245.35M-$-211.17M-$-248.95M-$-186.58M-$-223.75M
Total assets$2.27B$926.1M$564.1M$631.4M$531.4M
Total debt$1.33B$468.1M$488.1M$433M$239M
Net debt$722.3M$127.1M$322.4M$130.1M-$-38.74M
Total equity$491.3M$56.3M-$-1.38B-$-1.13B-$-807.49M
Cash and short-term investments$755M$448.3M$197.6M$302.9M$277.7M
Income statement
20252024202320222021
Revenue$1.27B$693.4M$531.8M$320.7M$257.9M
Cost of revenue$473.9M$312.3M$245.7M$190.5M$174.2M
Gross profit$797.9M$381.1M$286.2M$130.2M$83.6M
Research and development expenses$319M$316.8M$185.5M$162.3M$128.4M
Selling, general and administrative expenses$715.4M$755.4M$296.8M$233.4M$199M
Other expenses$16.3M$0.00$0.00$0.00$0.00
Operating expenses$1.05B$1.07B$482.3M$395.6M$327.4M
Cost and expenses$1.52B$1.38B$727.9M$586.1M$501.6M
Interest income$12.6M$11.1M$7.6M$3.03M$620K
Interest expense$70.3M$53.7M$46.9M$21.9M$15.2M
Depreciation and amortization$102.3M$37.2M$33.3M$30.4M$23.9M
Ebitda-$-118.51M-$-610.42M-$-133.33M-$-236.85M-$-219.52M
Operating income-$-252.87M-$-691.08M-$-196.08M-$-265.44M-$-243.71M
Total other income/expenses, net-$-43.84M-$-14.46M-$-17.75M-$-24.3M-$-15.48M
Income before tax-$-296.71M-$-705.54M-$-213.83M-$-289.75M-$-259.19M
Income tax expense-$-51.68M$270K$290K$70K$0.00
Net income-$-245.03M-$-705.81M-$-214.12M-$-289.81M-$-259.19M
Weighted average shares outstanding$174.3M$162.1M$154.2M$169.9M$169.9M
Weighted average diluted shares outstanding$174.3M$162.1M$154.2M$169.9M$169.9M
Balance sheet
20252024202320222021
Cash and short-term investments$755M$448.3M$197.6M$302.9M$277.7M
Net receivables$320M$154.8M$94.5M$88.7M$82.2M
Inventory$51.7M$38.4M$28.8M$22.3M$22.9M
Total current assets$1.17B$667.6M$350.3M$438.6M$404M
Property, plant and equipment, net$153.7M$72.8M$82.2M$67.8M$35.4M
Goodwill and intangible assets$825.5M$85.1M$95.3M$90.4M$53.3M
Long-term investments$86.6M$91.5M$0.00$0.00$0.00
Total non-current assets$1.11B$258.5M$213.7M$192.7M$127.4M
Total assets$2.27B$926.1M$564.1M$631.4M$531.4M
Accounts payable$82M$53.8M$54.4M$46M$33.8M
Short-term debt$13.4M$6.46M$6.44M$6.36M$420K
Deferred revenue$108.6M$91.9M$64.9M$50.1M$16.5M
Total current liabilities$372.4M$291.1M$232.6M$174.2M$114.8M
Long-term debt$1.31B$461.6M$481.7M$426.7M$238.5M
Deferred revenue, non-current$28.4M$30.6M$16.8M$35.1M$0.00
Total non-current liabilities$1.41B$578.7M$1.71B$1.59B$1.22B
Capital lease obligations$87.6M$32.7M$38.5M$43.5M$710K
Total liabilities$1.78B$869.8M$1.95B$1.76B$1.34B
Common stock$20K$20K$10K$10K$10K
Retained earnings-$-2.4B-$-2.15B-$-1.4B-$-1.14B-$-807.49M
Accumulated other comprehensive income (loss)$900K$90K$10K$20K-$-10K
Total equity$491.3M$56.3M-$-1.38B-$-1.13B-$-807.49M
Total investments$236.8M$198.8M$31.8M$0.00$0.00
Total debt$1.33B$468.1M$488.1M$433M$239M
Net debt$722.3M$127.1M$322.4M$130.1M-$-38.74M
Cash flow statement
20252024202320222021
Net income-$-245.03M-$-705.81M-$-214.12M-$-289.81M-$-259.19M
Depreciation and amortization$102.3M$37.2M$33.3M$30.4M$23.9M
Stock-based compensation$124.8M$534.1M$0.00$0.00$560K
Change in working capital-$-178.55M-$-37.8M-$-37.84M$71.8M$14.6M
Accounts receivable-$-90.4M-$-61.04M-$-7.35M-$-8.2M$4.75M
Inventory-$-3.37M-$-9.54M-$-6.56M-$-1.31M$14.7M
Accounts payable-$-7.24M-$-23.85M-$-23.36M-$-7.92M-$-30.47M
Net cash provided by operating activities-$-218.09M-$-189.04M-$-214.34M-$-168.2M-$-211.98M
Investments in property, plant and equipment-$-21.05M-$-22.12M-$-34.61M-$-18.38M-$-11.77M
Acquisitions, net-$-376.67M-$-95.19M-$-5.71M-$-39.56M-$-5.96M
Net cash used for investing activities-$-398.36M-$-130.39M-$-40.31M-$-57.94M-$-21.72M
Common stock issued$195.5M$382M$0.00$0.00$0.00
Common stock repurchased-$-3.04M$0.00-$-3.6M$0.00$0.00
Dividends paid$0.00-$-5.62M-$-5.62M-$-5.62M-$-5.62M
Net cash used for financing activities$884.1M$494.3M$117.6M$251.4M-$-2.04M
Net change in cash$267.6M$175.2M-$-137.12M$25.3M-$-235.75M
Cash at end of period$609.5M$341.8M$166.6M$303.7M$278.5M
Operating cash flow-$-218.09M-$-189.04M-$-214.34M-$-168.2M-$-211.98M
Capital expenditure-$-27.27M-$-22.12M-$-34.61M-$-18.38M-$-11.77M
Free cash flow-$-245.35M-$-211.17M-$-248.95M-$-186.58M-$-223.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tempus AI, Inc.

        Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

        CEO
        Eric Lefkofsky
        Employees
        3.8K
        Beta
        3.46

        Explore

        Frequently asked questions

        What is the intrinsic value of Tempus AI, Inc. (TEM)?

        Tempus AI, Inc. (TEM) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TEM undervalued?

        TEM trades at a price of $54.04 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.